148 related articles for article (PubMed ID: 21038410)
1. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6.
Lam KD; Trinh HN; Do ST; Nguyen TT; Garcia RT; Nguyen T; Phan QQ; Nguyen HA; Nguyen KK; Nguyen LH; Nguyen MH
Hepatology; 2010 Nov; 52(5):1573-80. PubMed ID: 21038410
[TBL] [Abstract][Full Text] [Related]
2. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
Gill U; Aziz H; Gill ML
Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C.
Thu Thuy PT; Bunchorntavakul C; Tan Dat H; Rajender Reddy K
J Hepatol; 2012 May; 56(5):1012-1018. PubMed ID: 22266603
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
[TBL] [Abstract][Full Text] [Related]
6. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.
Brady DE; Torres DM; An JW; Ward JA; Lawitz E; Harrison SA
Clin Gastroenterol Hepatol; 2010 Jan; 8(1):66-71.e1. PubMed ID: 19747986
[TBL] [Abstract][Full Text] [Related]
7. Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial.
Liu CH; Huang CF; Liu CJ; Dai CY; Huang JF; Lin JW; Liang CC; Yang SS; Lin CL; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Kao JH; Yu ML
Sci Rep; 2015 Jul; 5():11710. PubMed ID: 26130141
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
9. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
10. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.
Hlaing NK; Banerjee D; Mitrani R; Arker SH; Win KS; Tun NL; Thant Z; Win KM; Reddy KR
World J Gastroenterol; 2016 Nov; 22(43):9613-9622. PubMed ID: 27920482
[TBL] [Abstract][Full Text] [Related]
12. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial.
Liu CH; Huang CF; Liu CJ; Dai CY; Huang JF; Lin JW; Liang CC; Yang SS; Lin CL; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Kao JH; Yu ML
Sci Rep; 2015 Oct; 5():15255. PubMed ID: 26469083
[TBL] [Abstract][Full Text] [Related]
14. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
[TBL] [Abstract][Full Text] [Related]
15. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.
Zeuzem S; Yoshida EM; Benhamou Y; Pianko S; Bain VG; Shouval D; Flisiak R; Rehak V; Grigorescu M; Kaita K; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG
Hepatology; 2008 Aug; 48(2):407-17. PubMed ID: 18666223
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
Carr C; Hollinger FB; Yoffe B; Wakil A; Phillips J; Bzowej N; Leung J; Mirro K; Poordad F; Moore DH; Gish RG
Liver Int; 2007 Oct; 27(8):1111-8. PubMed ID: 17845540
[TBL] [Abstract][Full Text] [Related]
17. Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.
Jin YJ; Lee JW; Lee JI; Park SH; Park CK; Kim YS; Jeong SH; Kim YS; Kim JH; Hwang SG; Rim KS; Yim HJ; Cheong JY; Cho SW; Lee JS; Park YM; Jang JW; Lee CK; Sohn JH; Yang JM; Han S
BMC Gastroenterol; 2013 Apr; 13():74. PubMed ID: 23627926
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.
Jacobson IM; Brown RS; Freilich B; Afdhal N; Kwo PY; Santoro J; Becker S; Wakil AE; Pound D; Godofsky E; Strauss R; Bernstein D; Flamm S; Pauly MP; Mukhopadhyay P; Griffel LH; Brass CA;
Hepatology; 2007 Oct; 46(4):971-81. PubMed ID: 17894303
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.
Liu CH; Liu CJ; Lin CL; Liang CC; Hsu SJ; Yang SS; Hsu CS; Tseng TC; Wang CC; Lai MY; Chen JH; Chen PJ; Chen DS; Kao JH
Clin Infect Dis; 2008 Nov; 47(10):1260-9. PubMed ID: 18834319
[TBL] [Abstract][Full Text] [Related]
20. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.
Zeuzem S; Sulkowski MS; Lawitz EJ; Rustgi VK; Rodriguez-Torres M; Bacon BR; Grigorescu M; Tice AD; Lurie Y; Cianciara J; Muir AJ; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG;
Gastroenterology; 2010 Oct; 139(4):1257-66. PubMed ID: 20600013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]